Geron Corporation
GERN · NASDAQ
Bulios Fair Price
$1.61
31.4% upside
Current Price
$1.23
According to Bulios Fair Price, GERN is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Geron Corporation is an American biotechnology company focused on researching and developing therapeutic drugs for the treatment of various oncological diseases and other serious conditions. The company specializes in telomerase inhibition therapy, a process that targets the suppression of uncontrolled cell growth in cancerous conditions. Geron Corporation focuses on clinical trials and drug development with the potential to alleviate patient suffering and improve their quality of life. The company also has research and licensing programs for the development of new therapeutic drugs. Investing in Geron Corporation (GERN) shares may be an interesting choice for investors who follow the biotechnology industry and seek investment opportunities in a company with an innovative approach to treating serious diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Harout Semerjian
Employees
258
Headquarters
Foster City
Upcoming events
Earnings
Upcoming earnings report